CBP-4888

CBP-4888 is an investigational, placenta-targeted **small interfering RNA** therapy developed by Comanche Biopharma for **sFlt1-mediated preterm preeclampsia**. It is a fixed-dose combination of two chemically synthesized, lipid-conjugated siRNA duplex oligonucleotides designed to silence two soluble fms-like tyrosine kinase 1 messenger RNA isoforms in the placenta, thereby reducing pathological overproduction of soluble fms-like tyrosine kinase 1, a circulating anti-angiogenic driver of maternal vascular dysfunction in preeclampsia. The product is administered by subcutaneous injection and is in Phase 1 clinical development, including a study in hospitalized participants with preterm preeclampsia receiving standard-of-care expectant management. ([comanchebiopharma.com](https://comanchebiopharma.com/comanche-biopharma-receives-us-fda-fast-track-designation-for-cbp-4888-for-the-treatment-of-sflt-1-mediated-pre-term-preeclampsia/))

Other names

siRNA-2283siRNA2283siRNA 2283siRNA-2519siRNA2519siRNA 2519